• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺结节的评估与管理:现状与未来展望

Evaluation and management of pulmonary nodules: state-of-the-art and future perspectives.

作者信息

Sayyouh Mohamed, Vummidi Dharshan R, Kazerooni Ella A

机构信息

University of Michigan Health System, Division of Cardiothoracic Radiology, Department of Radiology , Ann Arbor, MI , USA

出版信息

Expert Opin Med Diagn. 2013 Nov;7(6):629-44. doi: 10.1517/17530059.2013.858117.

DOI:10.1517/17530059.2013.858117
PMID:24175679
Abstract

INTRODUCTION

The imaging evaluation of pulmonary nodules, often incidentally detected on imaging examinations performed for other clinical reasons, is a frequently encountered clinical circumstance. With advances in imaging modalities, both the detection and characterization of pulmonary nodules continue to evolve and improve.

AREAS COVERED

This article will review the imaging modalities used to detect and diagnose benign and malignant pulmonary nodules, with a focus on computed tomography (CT), which continues to be the mainstay for evaluation. The authors discuss recent advances in the lung nodule management, and an algorithm for the management of indeterminate pulmonary nodules.

EXPERT OPINION

There are set of criteria that define a benign nodule, the most important of which are the lack of temporal change for 2 years or more, and certain benign imaging criteria, including specific patterns of calcification or the presence of fat. Although some indeterminate pulmonary nodules are immediately actionable, generally those approaching 1 cm or larger in diameter, at which size the diagnostic accuracy of tools such as positron emission tomography (PET)/CT, single photon emission CT (SPECT) and biopsy techniques are sufficient to warrant their use. The majority of indeterminate pulmonary nodules are under 1 cm, for which serial CT examinations through at least 2 years for solid nodules and 3 years for ground-glass nodules, are used to demonstrate either benign biologic behavior or otherwise. The management of incidental pulmonary nodules involves a multidisciplinary approach in which radiology plays a pivotal role. Newer imaging and postprocessing techniques have made this a more accurate technique eliminating ambiguity and unnecessary follow-up.

摘要

引言

肺结节的影像学评估在临床上经常遇到,这些结节通常是在因其他临床原因进行的影像学检查中偶然发现的。随着成像技术的进步,肺结节的检测和特征描述不断发展和改进。

涵盖领域

本文将回顾用于检测和诊断良性及恶性肺结节的成像技术,重点是计算机断层扫描(CT),它仍然是评估的主要手段。作者讨论了肺结节管理的最新进展,以及不确定肺结节的管理算法。

专家观点

有一系列标准来定义良性结节,其中最重要的是两年或更长时间内没有时间变化,以及某些良性影像学标准,包括特定的钙化模式或脂肪的存在。虽然一些不确定的肺结节可以立即采取行动,但一般来说,那些直径接近或大于1厘米的结节,在这个尺寸下,正电子发射断层扫描(PET)/CT、单光子发射CT(SPECT)和活检技术等工具的诊断准确性足以保证其使用。大多数不确定的肺结节直径小于1厘米,对于实性结节,通过至少2年的连续CT检查,对于磨玻璃结节,则通过3年的连续CT检查,以证明其良性生物学行为或其他情况。偶然发现的肺结节的管理涉及多学科方法,其中放射学起着关键作用。更新的成像和后处理技术使这一技术更加准确,消除了模糊性和不必要的随访。

相似文献

1
Evaluation and management of pulmonary nodules: state-of-the-art and future perspectives.肺结节的评估与管理:现状与未来展望
Expert Opin Med Diagn. 2013 Nov;7(6):629-44. doi: 10.1517/17530059.2013.858117.
2
Solitary pulmonary nodule: detection and management.孤立性肺结节:检测与管理
Cancer Imaging. 2006 Oct 31;6(Spec No A):S42-6. doi: 10.1102/1470-7330.2006.9004.
3
Improvement in imaging diagnosis technique and modalities for solitary pulmonary nodules: from ground-glass opacity nodules to part-solid and solid nodules.孤立性肺结节影像诊断技术及方式的进展:从磨玻璃密度结节到部分实性及实性结节。
Expert Rev Respir Med. 2016;10(3):261-78. doi: 10.1586/17476348.2016.1141053. Epub 2016 Feb 2.
4
99mTc-tetrofosmin SPECT in solitary pulmonary nodule evaluation.99m锝-替曲膦单光子发射计算机断层扫描在孤立性肺结节评估中的应用
Oncol Rep. 2006 Oct;16(4):763-9.
5
Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.孤立性肺结节的特征:18F-FDG PET与结节增强CT的对比
AJR Am J Roentgenol. 2006 Nov;187(5):1361-7. doi: 10.2214/AJR.05.1166.
6
Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT.使用 320 层螺旋 CT 定量首过灌注成像与 FDG PET/CT 鉴别肺良恶性结节。
Radiology. 2011 Feb;258(2):599-609. doi: 10.1148/radiol.10100245.
7
A visual and semi-quantitative assessment of (99m)Tc-EDDA/HYNIC-TOC scintigraphy in differentiation of solitary pulmonary nodules.(99m)Tc-EDDA/HYNIC-TOC 闪烁扫描术在孤立性肺结节鉴别诊断中的视觉及半定量评估
Nucl Med Rev Cent East Eur. 2004;7(2):143-50.
8
Management of incidental pulmonary nodules: current strategies and future perspectives.偶然发现的肺结节的处理:当前策略和未来展望。
Expert Rev Respir Med. 2020 Feb;14(2):173-194. doi: 10.1080/17476348.2020.1697853. Epub 2019 Dec 3.
9
Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions.孤立性肺结节:第一部分。良恶性病变鉴别的形态学评估。
Radiographics. 2000 Jan-Feb;20(1):43-58. doi: 10.1148/radiographics.20.1.g00ja0343.
10
Pulmonary nodule characterization, including computer analysis and quantitative features.肺结节特征描述,包括计算机分析和定量特征。
J Thorac Imaging. 2015 Mar;30(2):139-56. doi: 10.1097/RTI.0000000000000137.

引用本文的文献

1
The development and validation of a radiomic nomogram for the preoperative prediction of lung adenocarcinoma.一种用于术前预测肺腺癌的放射组学列线图的开发和验证。
BMC Cancer. 2020 Jun 8;20(1):533. doi: 10.1186/s12885-020-07017-7.
2
Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.鉴定蛋白质组学特征以区分肺良性结节和肺腺癌。
J Proteome Res. 2017 Sep 1;16(9):3266-3276. doi: 10.1021/acs.jproteome.7b00245. Epub 2017 Aug 8.
3
A Systematic Review and Meta-Analysis of C-Arm Cone-Beam CT-Guided Percutaneous Transthoracic Needle Biopsy of Lung Nodules.
C型臂锥形束CT引导下肺结节经皮经胸针吸活检的系统评价与Meta分析
Pol J Radiol. 2017 Mar 19;82:152-160. doi: 10.12659/PJR.899626. eCollection 2017.
4
Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules.预测肺结节癌症状态的放射学图像特征
Clin Cancer Res. 2017 Mar 15;23(6):1442-1449. doi: 10.1158/1078-0432.CCR-15-3102. Epub 2016 Sep 23.